Volume 15, Issue 5, Pages (May 2007)

Slides:



Advertisements
Similar presentations
Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Advertisements

Volume 15, Issue 6, Pages (June 2007)
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Volume 10, Issue 2, Pages (August 2004)
Volume 16, Issue 3, Pages (March 2008)
Volume 17, Issue 9, Pages (September 2009)
Volume 25, Issue 10, Pages (October 2017)
Volume 19, Issue 1, Pages (July 2003)
Loss of Extracellular Superoxide Dismutase Induces Severe IL-23-Mediated Skin Inflammation in Mice  Yun Sang Lee, In-Su Cheon, Byung-Hak Kim, Myung-Ja.
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Volume 15, Issue 2, Pages (February 2007)
Dermal Vγ4+ γδ T Cells Possess a Migratory Potency to the Draining Lymph Nodes and Modulate CD8+ T-Cell Activity through TNF-α Production  Satoshi Nakamizo,
Volume 25, Issue 3, Pages (March 2017)
Upregulation of Inflammatory Cytokines and Oncogenic Signal Pathways Preceding Tumor Formation in a Murine Model of T-Cell Lymphoma in Skin  Xuesong Wu,
Targeting Improves MSC Treatment of Inflammatory Bowel Disease
Volume 15, Issue 1, Pages (January 2007)
Volume 12, Issue 6, Pages (December 2005)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Α-MSH-Stimulated Tolerogenic Dendritic Cells Induce Functional Regulatory T Cells and Ameliorate Ongoing Skin Inflammation  Matteo Auriemma, Thomas Brzoska,
Volume 25, Issue 3, Pages (March 2017)
Molecular Therapy - Oncolytics
Volume 18, Issue 10, Pages (October 2010)
Volume 13, Issue 3, Pages (September 2000)
Volume 23, Issue 5, Pages (May 2015)
Volume 10, Issue 1, Pages (July 2004)
Volume 25, Issue 11, Pages (November 2017)
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)‏ by Michaela Scherr, Anuhar Chaturvedi, Karin.
Volume 26, Issue 4, Pages (April 2018)
Volume 9, Issue 4, Pages (April 2004)
Volume 25, Issue 1, Pages (January 2017)
Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor  Alexander Falkenhagen, Jastaranpreet Singh, Sabah Asad, Danila Leontyev,
Volume 23, Issue 4, Pages (April 2015)
by Kalpana Parvathaneni, and David W. Scott
Volume 18, Issue 9, Pages (September 2010)
Volume 5, Issue 2, Pages (February 2002)
Volume 18, Issue 4, Pages (April 2010)
Volume 22, Issue 5, Pages (May 2014)
Volume 13, Issue 2, Pages (February 2006)
Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node  Lifang Cheng,
Pathophysiological Characteristics of Melanoma In-Transit Metastasis in a Lymphedema Mouse Model  Kohei Oashi, Hiroshi Furukawa, Hiroshi Nishihara, Michitaka.
Volume 19, Issue 2, Pages (February 2011)
Volume 13, Issue 2, Pages (February 2006)
Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects  Jeffrey S. Moyer, Gabriel.
Volume 19, Issue 9, Pages (May 2017)
Volume 15, Issue 11, Pages (November 2007)
Volume 15, Issue 4, Pages (April 2007)
Volume 11, Issue 6, Pages (June 2005)
Volume 18, Issue 8, Pages (August 2010)
Volume 24, Issue 1, Pages (January 2016)
Volume 22, Issue 2, Pages (February 2014)
Volume 26, Issue 1, Pages (January 2018)
Volume 17, Issue 10, Pages (October 2009)
Volume 15, Issue 7, Pages (July 2007)
Volume 15, Issue 9, Pages (September 2007)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response  Arup Garu, Gopikrishna.
Volume 23, Issue 3, Pages (March 2015)
CpG Immunostimulatory Sequences Enhance Contact Hypersensitivity Responses in Mice  Hitoshi Akiba, Masataka Satoh, Keiji Iwatsuki, Dominique Kaiserlian,
Volume 23, Issue 4, Pages (April 2015)
Molecular Therapy - Oncolytics
Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy  Zhenmei Lu, Soosan.
Volume 20, Issue 6, Pages (June 2012)
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Volume 7, Issue 3, Pages (March 2003)
Volume 3, Issue 5, Pages (May 2001)
Volume 23, Issue 6, Pages (June 2015)
Volume 11, Issue 5, Pages (May 2005)
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Volume 25, Issue 4, Pages (April 2017)
Presentation transcript:

Volume 15, Issue 5, Pages 971-980 (May 2007) Lentiviral Vector–mediated Autonomous Differentiation of Mouse Bone Marrow Cells into Immunologically Potent Dendritic Cell Vaccines  Richard C Koya, Takahiro Kimura, Antoni Ribas, Nora Rozengurt, Gregory W Lawson, Emmanuelle Faure-Kumar, He-jing Wang, Harvey Herschman, Noriyuki Kasahara, Renata Stripecke  Molecular Therapy  Volume 15, Issue 5, Pages 971-980 (May 2007) DOI: 10.1038/mt.sj.6300126 Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 1 Lentiviral vectors and experimental design. (a) Diagram representing the bicistronic [simultaneously expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4] and monocistronic vectors [expressing luciferase or green fluorescent protein (GFP) marking genes or expressing MART1 and TRP2 tumor antigens]. The long terminal repeats (LTRs), the splice donor site (SD), the splice acceptor site (SA), the packaging signal Ψ, the cytomegalovirus (CMV) enhancer/promoter element, the truncated and out-of-frame gag gene (Ga) upstream to the Rev responsive element (RRE), the central polypurine and termination sequence (cPPT), the woodchuck hepatitis pre element (Wpre), and the self-inactivating mutation in the 3′ LTR (ΔU3) are indicated (not to scale). The bicistronic construct contains an internal ribosome entry site (IRES) upstream of the mouse IL-4 open reading frame. (b) Experimental design for the different transduction protocols: generation of conventional DCs, in vitro self-differentiated DC/LV-GI4 cells, or in vivo differentiated BM/LV-GI4 cells. Molecular Therapy 2007 15, 971-980DOI: (10.1038/mt.sj.6300126) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 2 Characteristics of DC/LV-GI4 cells self-differentiated ex vivo. Flow cytometry analyses of DC/LV-GI4-LUC on days 7 and 14 of culture recapitulate immunophenotype of conventional DC/LV-LUC: CD11chigh, CD11blow, CD80+, MHCII+. Molecular Therapy 2007 15, 971-980DOI: (10.1038/mt.sj.6300126) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 3 In vivo viability and lymphadenopathy after injection of conventional DC/LV-LUC or DC/LV-GI4-LUC s.c. into C57BL/6 mice. (a) The panel shows photographs obtained by optical imaging analyses of the injection site and inguinal region at different times. High levels of luciferase signal are shown in red and low levels in blue, as indicated by the reference color bar. The histogram shows the quantified values of bioluminescence signal on a logarithmic scale for conventional DC/LV-LUC (dots) or DC/LV-GI4-LUC (black). Mixed-model statistical analyses comparing the bioluminescence signal between mice in each study group with 12 measurements total did not yielded significant values (P = 0.0744). (b) Histopathological (hematoxylin and eosin) and immunohistochemical (hematoxylin and anti-CD11c) analyses of inguinal lymph nodes (LNs) demonstrating that at 7 days after DC/LV-GI4-LUC injection, a conspicuous lymphoadenopathy is observed, which is associated with higher frequency of CD11c+ cells, likely DCs. Molecular Therapy 2007 15, 971-980DOI: (10.1038/mt.sj.6300126) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 4 In vivo superior viability, self-differentiation, and migration of BM/LV-GI4-LUC cells injected subcutaneously (s.c.) into C57BL/6 mice. (a) Photographs obtained by optical imaging analyses of the injection site and inguinal region of mice at different times. High levels of luciferase signal are shown in red and low signals in blue, as indicated by the reference color bar. The histogram shows the quantified values of bioluminescence signal on a logarithmic scale for BM/LV-LUC (dots) or BM/LV-GI4-LUC cells (black). Mixed-model statistical analyses comparing the bioluminescence signal between mice in each study group with 18 measurements total yielded significant values (injection site P = 0.0408 and inguinal region P = 0.0063). (b) Immunohistochemical (hematoxylin and anti-CD11c or anti-LUC) analyses of injected skin (flanks) showing the presence of CD11c+LUC+ cells in the epidermis and dermis of mice injected with BM/LV-GI4-LUC (arrows). (c) Immunohistochemical (hematoxylin and anti-CD11c or anti-GFP) analyses of injected skin (ears) showing the accumulation of CD11c+GFP+ cells in the dermis of mice injected with BM/LV-GI4-GFP (arrows). (d) Histopathological (hematoxylin and eosin) and immunohistochemical (hematoxylin and anti-CD11c) analyses of inguinal lymph nodes (LNs) demonstrating that at 7 days after injection with BM/LV-GI4-LUC, a conspicuous lymphadenopathy is observed, which is associated with increased frequency of CD11c+ cells. (e) Large view (×4, upper panels) and high-magnification view (×100, lower panels) of immunohistochemical analyses (hematoxylin, anti-CD11c, and anti-GFP) of LN obtained from mice injected with BM/LV-GI4-GFP showing co-localization of large cells positive for CD11c and GFP (arrows). Molecular Therapy 2007 15, 971-980DOI: (10.1038/mt.sj.6300126) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 5 Protection against B16 melanoma challenge after vaccination with BM/LV-GI4-MART1. Upper panel shows the experimental schedule for vaccinations and challenge. (a) Sub-lethal B16 challenge dose (1 × 104 cells): phosphate-buffered saline (PBS) injection control (green), two vaccinations with day-7 conventional DC/LV-MART1 gene (red), or vaccination with day-1 BM/LV-GI4-MART1 (orange). Kaplan–Meier analyses (frequency of survivors over time) is shown for the different treatment groups. Significance values (P) were calculated by log rank test relative to the PBS control. (b) Lethal B16 challenge dose (5 × 104 cells): PBS injection control (green), vaccination with day-7 DC/LV-GI4-MART1 (blue), or vaccination with day-1 BM/LV-GI4-MART1 (orange). Molecular Therapy 2007 15, 971-980DOI: (10.1038/mt.sj.6300126) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 6 MART1-specific effector function after vaccination with DC/LV-GI4-MART1 or BM/LV-GI4-MART1. Chromium release assay was performed with splenocytes at several effector-to-target ratios after mice were vaccinated with phosphate-buffered saline (PBS) (open circles), conventional DC/LV-MART1 (triangles), DC/LV-GI4-MART1 (closed circles), or BM/LV-GI4- MART1 (squares). Molecular Therapy 2007 15, 971-980DOI: (10.1038/mt.sj.6300126) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions